NEW DELHI – While the recent FDA approval for a biosimilar version of Roche Holding AG's cancer drug, Herceptin (trastuzumab), developed by Mylan NV and Indian company Biocon Ltd., was notable as the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, the approval also gives a huge fillip to India's nascent and emerging biosimilars industry.